We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00054730
Recruitment Status : Completed
First Posted : February 11, 2003
Last Update Posted : June 24, 2005
Information provided by:

February 7, 2003
February 11, 2003
June 24, 2005
June 2002
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Effects of CX516 on Functioning in Fragile X Syndrome and Autism
Effects of Ampakine CX516 (Ampalex®) on Functioning in Fragile X Syndrome and Autism

This study will investigate whether CX516 can improve attention, memory, language, or behavior in adults with Fragile X Syndrome and/or Autism.

CX516 is an AMPAKINE® compound. AMPAKINE compounds enhance synaptic strength. There is evidence to suggest that the synapses in the brain of an individual with fragile X syndrome are immature and abnormal. It is possible CX516 may partially correct this synaptic transmission defect and lead to improvement in cognitive and behavioral functioning.

There is also reason to believe that these changes caused by CX516 could be helpful in managing cognitive and behavioral symptoms in patients with autistic disorder.

Involvement for each participant will last 28 days. Participants will be given study medication, a physical exam, and a variety of cognitive assessment tests to study potential drug effectiveness at improving disease symptoms.

Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Fragile X Syndrome
  • Autism
Drug: CX516 (Ampalex®)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
Not Provided
Not Provided

Inclusion criteria:

Fragile X group

  • DNA-based diagnosis of Fragile X syndrome

Autism group

  • Documented diagnosis with ADOS; ADI-R; CARS and GARS

Both groups

  • 18-50 years
  • Measured IQ below 85
  • Measured IQ >20
  • Mental age >30 months
  • Stable medication regimen for past 8 weeks
  • Normal hearing
  • Vision corrected to at least 20/50
  • All females of childbearing age must have a negative pregnancy test at enrollment

Exclusion criteria:

  • Recent history of seizure, epilepsy, or blackouts
  • Unresolved medical issue impacting performance
  • Behavioral dysfunction to the point that subject cannot cooperate for testing
  • History of drug-induced neutropenia
  • Uncontrolled hypertension
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
FRAXA Research Foundation
Not Provided
February 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP